• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Intellia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    2/21/25 4:06:02 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    8-K
    false 0001652130 0001652130 2025-02-18 2025-02-18

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): February 18, 2025

     

     

    INTELLIA THERAPEUTICS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-37766   36-4785571

    (State or Other Jurisdiction

    of Incorporation)

      (Commission
    File Number)
     

    (IRS Employer

    Identification No.)

     

    40 Erie Street, Suite 130

    Cambridge, Massachusetts

      02139
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (857) 285-6200

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock (Par Value $0.0001)   NTLA   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On February 18, 2025, Intellia Therapeutics, Inc. (the “Company”) entered into a Lease Agreement (the “Tech Square Lease”) with ARE-Tech Square, LLC, an affiliate of Alexandria Real Estate Equities, Inc. (the “Tech Square Landlord”) for office and laboratory space located at 400 Technology Square, Cambridge, Massachusetts (“400 Tech Square”). Under the terms of the Tech Square Lease, the Company will initially lease approximately 101,000 square feet at 400 Tech Square (the “Initial Tech Square Premises”), which will supplement, and eventually replace certain parts of, the Company’s current leased premises in Cambridge, Massachusetts. In addition, the Tech Square Lease will expand, in two tranches, to include approximately 46,000 square feet of additional office and laboratory space at 400 Tech Square (the “Additional Tech Square Premises”) when each such space becomes available. The Tech Square Lease is expected to commence on July 1, 2025 (the “Commencement Date”) with respect to the Initial Tech Square Premises, and the Company’s obligation to pay rent will start on the date that is approximately 14 months after the Commencement Date (the “Rent Commencement Date”). In addition, the lease of the Additional Tech Square Premises will commence when the Tech Square Landlord delivers such space to the Company, which is anticipated to occur in December 2027 and January 2028 (in each case, an “Additional Premises Commencement Date”), and the Company’s obligation to pay rent for such Additional Tech Square Premises will start on the date that is approximately 14 months after each Additional Premises Commencement Date (in each case, an “Additional Premises Rent Commencement Date”). The Company shall not be obligated to pay the base rent for the applicable premises for three months after the Rent Commencement Date and each Additional Premises Rent Commencement Date, as applicable. The initial term of the Tech Square Lease is twelve years and three months following the Rent Commencement Date, and the Company has an option to extend the 400 Tech Square Lease for an additional term of five years. As of the Rent Commencement Date, the base rent under the Tech Square Lease is expected to be $108.00 per square foot per year, plus certain operating expenses and taxes; provided that the initial base rent may adjust based on certain criteria set forth in the lease. The base rent is subject to scheduled annual increases of 3% on the anniversary of the Commencement Date. In addition, the Tech Square Landlord will contribute up to $41.5 million toward the cost of construction and tenant improvements for the Initial Tech Square Premises, and an additional amount toward the cost of construction and tenant improvements for the Additional Tech Square Premises.

    In conjunction with the Tech Square Lease, on February 18, 2025, the Company entered into a Second Amendment to Lease (the “Winter Street Amendment”) that amends that certain Lease Agreement between the Company and ARE-Winter Street Property, LLC, an affiliate of Alexandria Real Estate Equities, Inc. (the “Winter Street Landlord”) for office and laboratory space located at 840 Winter Street, Waltham, Massachusetts (the “Winter Street Lease”). Pursuant to the Winter Street Amendment, the Winter Street Lease will terminate on or before June 30, 2028. The Company will pay to the Winter Street Landlord lease modification payments totaling $78 million in three installments in February 2025, April 2025, and January 2026, and the Company will not pay any base rent, operating expenses or other costs pursuant to the Winter Street Lease after January 2025.

    The foregoing descriptions of the terms of the Tech Square Lease and the Winter Street Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Tech Square Lease and the Winter Street Amendment, which will be filed with the Company’s Annual Report on Form 10-K for the period ended December 31, 2024.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03 of this Current Report on Form 8-K.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        Intellia Therapeutics, Inc.
    Date: February 21, 2025     By:  

    /s/ John M. Leonard

          Name: John M. Leonard
          Title: Chief Executive Officer and President
    Get the next $NTLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    3/2/2026Mkt Perform → Outperform
    William Blair
    11/12/2025Outperform → Peer Perform
    Wolfe Research
    11/11/2025$8.00Outperform → In-line
    Evercore ISI
    11/7/2025$5.00Neutral → Underweight
    Analyst
    10/28/2025$14.00Outperform → Sector Perform
    RBC Capital Mkts
    10/28/2025Outperform → Mkt Perform
    Bernstein
    10/27/2025Outperform → Mkt Perform
    William Blair
    10/27/2025Buy → Neutral
    Guggenheim
    More analyst ratings

    $NTLA
    SEC Filings

    View All

    SEC Form 424B5 filed by Intellia Therapeutics Inc.

    424B5 - Intellia Therapeutics, Inc. (0001652130) (Filer)

    3/2/26 4:13:13 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

    3/2/26 8:16:28 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-8 filed by Intellia Therapeutics Inc.

    S-8 - Intellia Therapeutics, Inc. (0001652130) (Filer)

    2/26/26 5:31:47 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intellia Therapeutics upgraded by William Blair

    William Blair upgraded Intellia Therapeutics from Mkt Perform to Outperform

    3/2/26 12:43:05 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Intellia Therapeutics from Outperform to Peer Perform

    11/12/25 8:54:37 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Intellia Therapeutics from Outperform to In-line and set a new price target of $8.00

    11/11/25 8:02:05 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    3/3/26 4:18:31 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Leonard John M was granted 156,400 shares, increasing direct ownership by 15% to 1,169,739 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    3/3/26 4:19:05 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VP, Chief Accounting Officer Dube Michael P was granted 17,250 shares, increasing direct ownership by 33% to 69,527 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    3/3/26 4:15:37 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

    Next-generation cellular therapies and regenerative medicine drive exponential expansionNEW YORK, March 3, 2026 /CNW/ -- Market News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for ways to stay healthier, more energetic, and more youthful. What was once considered a niche cosmetic category has evolved into a major healthcare and biotech opportunity. Industry forecasts project the broader anti-aging market could surpass $420 billion by 2030, growing at an estimated 8–9% compound annual growth rate (CAGR). This growth is being fueled by rising healthcare awareness, advances in biotechnology, and increased de

    3/3/26 9:00:00 AM ET
    $GERN
    $NAGE
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

    CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania. All posters are available on intelliatx.com on the Scientific Publications & Presentations page. Poster Presentation Details: Title: Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) 50 mg in Patients with Hereditary Angioedema

    3/3/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

    CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). "We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to

    3/2/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Financials

    Live finance-specific insights

    View All

    Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

    HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical com

    2/26/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference c

    2/19/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

    Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo-z on November 8 at ACAAI 2025Ended third quarter with approximately $670 million in cash, cash equivalents and marketable securities; expected to fund operations into mid-2027 Conference call today a

    11/6/25 4:00:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/13/24 5:07:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/29/24 4:00:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/24/24 11:21:06 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Leadership Updates

    Live Leadership Updates

    View All

    Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

    Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

    11/16/24 10:16:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

    10/24/24 8:01:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

    - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

    10/10/24 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care